Table 1 Characteristics of 6 trials included in this meta-analysis
Source | Year | Journal | Phase | Treatment | No. of patients | Median age | Primary endpoints | pCR in ITT(%) |
|---|---|---|---|---|---|---|---|---|
KEYNOTE-522, Schmid et al. [17] | 2020 | New England Journal of Medicine | 3 | E:Pembro+pac + Cb → AC C:pbo + pac + Cb → AC | 784 390 | 49(22–80) 48(24–79) | pCR and EFS in ITT | 64.8(260/401) 51.2(103/201) |
GeparNuevo study, Loibl et al. [19] | 2019 | Annals of Oncology | 2 | E:Durva+nab-pac → EC C:Pbo + nab-pac → EC | 88 86 | 49.5(23–76) | pCR in ITT | 53.4(47/88) 44.2(38/86) |
NeoTRIPaPDL1, Gianni et al. [21] | 2019 | Cancer Research | 3 | E:Atezo+Cb + nab-pac C: Cb + nab-pac | 138 142 | 50 | EFS | 43.5(60/138) 40.8(58/142) |
I-SPY2 Trial, Nanda et al. [18] | 2020 | JAMA oncology | 2 | E:Pembro+pac → AC C:Pbo + pac → AC | 29 85 | 50(27–71) 47(24–77) | pCR in ITT | 60(17/28) 22(17/79) |
Impassion031, Elizabethet al. [20] | 2020 | The Lancet | 3 | E:Atezo+nab-pac → AC C:Pbo + nab-pac → AC | 165 168 | 51(22–76) 51(26–78) | pCR in ITT and in PD-L1+ populations | 57.6(95/165) 41.1(69/168) |
Nci 10,013, Foluso et al. [22] | 2021 | Cancer Research | 2 | E:Atezo+pac + Cb C:Pac + Cb | 45 22 | 52(25–78) | pCR and TIL percentages in ITT | 55.6(25/45) 18.8(3/16) |